Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic gluconeogenesis is a metabolic pathway in the liver that synthesizes glucose from non-carbohydrate precursors, such as lactate, amino acids, and glycerol. This process is essential for maintaining blood glucose levels during fasting or intense exercise. Key enzymes involved include pyruvate carboxylase, phosphoenolpyruvate carboxykinase (PEPCK), fructose 1,6-bisphosphatase (FBPase), and glucose-6-phosphatase (G6Pase). Regulation occurs through hormonal control (insulin, glucagon, glucocorticoids) and transcriptional coactivators. Dysregulation contributes to hyperglycemia in type 2 diabetes, making it a potential therapeutic target.
Inhibition of key gluconeogenic enzymes (e.g., PEPCK, G6Pase) or modulation of regulatory hormones (insulin, glucagon, glucocorticoids).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic Gluconeogenesis Pathway.